| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 产品销售收入(元) | 614,022,476.05 | - | 526,371,791.39 | 877,515,834.49 | 451,127,695.90 |
| 技术收入(元) | - | 75,804,793.09 | 25,993,598.11 | 84,386,767.21 | 25,336,938.56 |
| 权益分成收入(元) | - | 61,903,401.02 | 31,736,060.69 | 51,387,587.16 | 22,182,478.52 |
| 抗病毒类(元) | - | 280,948,940.90 | - | - | - |
| 抗真菌类(元) | - | 254,028,874.81 | - | - | - |
| 免疫抑制类(元) | - | 56,302,854.81 | - | - | - |
| 制剂类(元) | - | 138,009,537.22 | - | - | - |
| 技术权益及服务收入(元) | 29,766,533.40 | - | - | - | - |
| 其他类产品(元) | - | 294,178,132.01 | - | - | - |
| 营业成本(元) | |||||
| 产品销售收入(元) | 283,869,053.93 | - | 250,600,521.64 | 361,843,143.15 | 182,789,515.69 |
| 技术收入(元) | - | 20,975,623.82 | 5,737,730.95 | 14,301,726.50 | 7,455,759.03 |
| 权益分成收入(元) | - | - | - | - | - |
| 抗病毒类(元) | - | 181,057,256.80 | - | - | - |
| 抗真菌类(元) | - | 70,362,335.41 | - | - | - |
| 免疫抑制类(元) | - | 29,644,044.62 | - | - | - |
| 制剂类(元) | - | 45,576,070.92 | - | - | - |
| 技术权益及服务收入(元) | 453,995.19 | - | - | - | - |
| 其他类产品(元) | - | 161,973,053.50 | - | - | - |
| 毛利(元) | |||||
| 产品销售收入(元) | 330,153,422.12 | - | 275,771,269.75 | 515,672,691.34 | 268,338,180.21 |
| 技术收入(元) | - | 54,829,169.27 | 20,255,867.16 | 70,085,040.71 | 17,881,179.53 |
| 权益分成收入(元) | - | 61,903,401.02 | 31,736,060.69 | 51,387,587.16 | 22,182,478.52 |
| 抗病毒类(元) | - | 99,891,684.10 | - | - | - |
| 抗真菌类(元) | - | 183,666,539.40 | - | - | - |
| 免疫抑制类(元) | - | 26,658,810.19 | - | - | - |
| 制剂类(元) | - | 92,433,466.30 | - | - | - |
| 技术权益及服务收入(元) | 29,312,538.21 | - | - | - | - |
| 其他类产品(元) | - | 132,205,078.51 | - | - | - |
| 毛利率(%) | |||||
| 产品销售收入(%) | 53.77 | - | 52.39 | 58.77 | 59.48 |
| 技术收入(%) | - | 72.33 | 77.93 | 83.05 | 70.57 |
| 权益分成收入(%) | - | - | - | - | - |
| 抗病毒类(%) | - | 35.56 | - | - | - |
| 抗真菌类(%) | - | 72.30 | - | - | - |
| 免疫抑制类(%) | - | 47.35 | - | - | - |
| 制剂类(%) | - | 66.98 | - | - | - |
| 技术权益及服务收入(%) | 98.47 | - | - | - | - |
| 其他类产品(%) | - | 44.94 | - | - | - |
| 收入构成(%) | |||||
| 产品销售收入(%) | 95.38 | - | 90.12 | 86.60 | 90.47 |
| 技术收入(%) | - | 6.53 | 4.45 | 8.33 | 5.08 |
| 权益分成收入(%) | - | 5.33 | 5.43 | 5.07 | 4.45 |
| 抗病毒类(%) | - | 24.20 | - | - | - |
| 抗真菌类(%) | - | 21.88 | - | - | - |
| 免疫抑制类(%) | - | 4.85 | - | - | - |
| 制剂类(%) | - | 11.89 | - | - | - |
| 技术权益及服务收入(%) | 4.62 | - | - | - | - |
| 其他类产品(%) | - | 25.33 | - | - | - |
| 毛利构成(%) | |||||
| 产品销售收入(%) | 91.85 | - | 84.14 | 80.93 | 87.01 |
| 技术收入(%) | - | 8.41 | 6.18 | 11.00 | 5.80 |
| 权益分成收入(%) | - | 9.50 | 9.68 | 8.07 | 7.19 |
| 抗病毒类(%) | - | 15.33 | - | - | - |
| 抗真菌类(%) | - | 28.19 | - | - | - |
| 免疫抑制类(%) | - | 4.09 | - | - | - |
| 制剂类(%) | - | 14.19 | - | - | - |
| 技术权益及服务收入(%) | 8.15 | - | - | - | - |
| 其他类产品(%) | - | 20.29 | - | - | - |